Related coverage linked through entity extraction aliases.
Apr 04, 2026
Experimental topical therapies for diabetic foot ulcers are showing early promise. Studies described probiotic-based treatments, a medieval antimicrobial mixture and a quercetin-loaded hyaluosome gel with anti-inflammatory and wound-healing effects.
Mar 24, 2026
The FDA has approved Bristol Myers Squibb's CAR-T therapy Breyanzi for relapsed/refractory marginal zone lymphoma, while a novel multiple myeloma drug candidate DTP3 advances to Phase 2 trials after showing promising early results. Both developments represent significant progress in blood cancer treatment, with the marginal zone lymphoma approval based on a 95.5% response rate and the myeloma drug demonstrating selective cancer cell killing without toxicity.
Mar 20, 2026
DelveInsight pipeline reports reveal robust clinical development across three cancer indications, with 45+ companies advancing cutaneous squamous cell carcinoma therapies, 70+ companies developing liver cancer treatments, and multiple hepatocellular carcinoma candidates receiving FDA designations in 2025-2026.
Mar 04, 2026
Can-Fite BioPharma's drug candidate namodenoson met its primary endpoint in a Phase 2a pancreatic cancer trial and demonstrated anti-obesity effects in a peer-reviewed preclinical study published in the International Journal of Obesity.
Feb 27, 2026
Research identifies orphan nuclear receptor SHP (NR0B2) as a novel regulator of osteoarthritis progression, demonstrating that it protects cartilage by inhibiting IKKβ/NF-κB signaling and reducing matrix-degrading enzyme expression in chondrocytes.
Feb 17, 2026
New research identifies circulating tumor-reactive T cell characteristics and inflammatory biomarkers as predictive indicators for immune checkpoint inhibitor response in cancer patients, while the PD-L1 testing market is projected to reach $36.44 billion by 2032.
